Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model
- 1 October 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (10)
- https://doi.org/10.1128/AAC.00854-20
Abstract
Candida auris has been shown to have a high risk of skin colonization in hospitalized patients, possibly contributing to nosocomial spread. In a guinea pig skin model, animals were evaluated for clinical appearance, tissue fungal burden, histology, and pharmacokinetics. Oral dosing with 10 mg/kg ibrexafungerp (IBX) reduced the severity of lesions and significantly reduced the C. auris fungal burden in infected animals compared with untreated controls. This indicates promise for use of IBX in controlling skin infection and colonization of hospitalized patients.This publication has 5 references indexed in Scilit:
- SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [ 14 C]SCY-078 in Albino and Pigmented RatsAntimicrobial Agents and Chemotherapy, 2019
- First hospital outbreak of the globally emerging Candida auris in a European hospitalAntimicrobial Resistance & Infection Control, 2016
- Tissue Penetration of Antifungal AgentsClinical Microbiology Reviews, 2014
- Nosocomial Candida glabrata Colonization: an Epidemiologic StudyJournal of Clinical Microbiology, 1998